Listing 1 - 6 of 6 |
Sort by
|
Choose an application
Choose an application
Apart from tumor characteristics, host factors play a pivotal role in the treatment of cancer. Even though it has been acknowledged since long that host immunity impacts tumor development and progression, extensive research into its prognostic and predictive value in BC has only been initiated more recently. Particularly, the role of the tumor immune infiltrate in the less immunogenic, but frequently diagnosed luminal breast tumors still remains largely unknown. Luminal BC actually is the most frequently diagnosed BC subtype, especially in older patients. As of yet, the tumor immune infiltrate in BC has mainly been studied via evaluating sTILs percentages. It might be more relevant, though, to assess the full immune contexture i.e. abundance, composition, functionality, and spatial distribution of the tumor immune infiltrate. BC is an age-related disease, hence age represents another crucial host factor, which has a substantial impact on BC biology and has been associated with inflammation, deterioration of immune functions (immunosenescence) and clinical frailty. Despite this, and despite the fact that the older population is rapidly growing, older patients with cancer are still largely underrepresented in clinical trials. Although enormous advances have been made in the BC field in general, the older patient population thus remains underexplored, making elderly cancer management very challenging for oncologists. The main objective of this PhD project was to obtain insights in the tumor immune landscape in luminal B-like tumors in relation to patient age and frailty, and to improve our scientific knowledge on the interplay between aging, immunity and cancer. The framework for the project was the IMAGE study, which included patients of different ages with luminal B-like BC.
Choose an application
Choose an application
Choose an application
The aim of this study is to investigate the association between plasma iron levels at diagnosis of early stage breast cancer and the risk of developing metastatic disease. In addition, a potential dependency on location of metastases and breast cancer subtype will be explored. A retrospective single-center approach was conducted on the database of the Multidisciplinary Breast Center of the University Hospital in Leuven. Patients newly diagnosed with stage I-III breast cancer between 2007-2017, whose serum iron, transferrin saturation and ferritin values were available within 1.5 months before or after diagnosis, were included in the study. Cox proportional hazard models were applied to determine the association between iron levels and risk of metastasis. 1113 patients were included, 10% of them developed distant metastasis. Transferrin saturation and serum iron were significantly associated with an increased risk of breast cancer metastasis. For each 10% increment of transferrin saturation, there was a 19% increase of metastatic risk (HR 1.19; 95% CI [1.02-1.38]). Similarly, a serum iron increment of 10 µg/dL led to a 6% increase in risk (HR 1.06; 95% CI [1.01-1.12]). Ferritin was found not to be associated with metastatic risk (HR 0.99; 95% CI [0.98, 1.01]). These results were adjusted for age, stage and subtype. However, there was no significant association with metastatic site or breast cancer subtype when adjusting for age and stage. We conclude that elevated transferrin saturation and serum iron at early breast cancer diagnosis are associated with increased risk for secondary metastatic disease. No association was found between iron levels and location of metastases or breast cancer subtype. Further research is needed to understand the underlying mechanisms and to explore the potential of iron-targeted therapies.
Choose an application
Listing 1 - 6 of 6 |
Sort by
|